Cinda L Hugos1,2, Michelle H Cameron3,4. 1. Department of Neurology, Oregon Health & Science University, 3303 SW Sam Jackson Park Rd., L226, Portland, OR, 97239, USA. hugosc@ohsu.edu. 2. VA Portland Health Care System, 3710 SW US Veterans Hospital Rd., R&D 27, Portland, OR, 97239, USA. hugosc@ohsu.edu. 3. Department of Neurology, Oregon Health & Science University, 3303 SW Sam Jackson Park Rd., L226, Portland, OR, 97239, USA. 4. VA MS Center of Excellence-West, VA Portland Health Care System, 3710 SW US Veterans Hospital Rd., Portland, OR, 97239, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to familiarize the reader with assessments and measurement of spasticity in people with multiple sclerosis (MS). Spasticity affects 60-84% of people with MS, worsening as disability worsens and impacting activity, participation, and quality of life. Spasticity manifests in many ways, including spasms, resistance to passive stretch, pain, and perception of tightness, and can affect muscles throughout the body, making assessment and quantification of spasticity challenging but important. Assessment tools include those quantified by clinicians, instrumentation, and patients. RECENT FINDINGS: Most tools for measuring spasticity are based on clinician scoring, were developed many years ago, and have undergone minimal recent advances. More recent developments are patient-reported outcome measures for spasticity, including the Numeric Rating Scale for Spasticity (NRS-S) and the disease-specific Multiple Sclerosis Spasticity Scale-88 (MSSS), and, most recently, imaging through elastography. MS-related spasticity is common and often disabling. There are various spasticity measurement tools available, each with advantages and limitations. Newer tools are likely to be developed as our understanding of spasticity in MS grows.
PURPOSE OF REVIEW: The purpose of this review is to familiarize the reader with assessments and measurement of spasticity in people with multiple sclerosis (MS). Spasticity affects 60-84% of people with MS, worsening as disability worsens and impacting activity, participation, and quality of life. Spasticity manifests in many ways, including spasms, resistance to passive stretch, pain, and perception of tightness, and can affect muscles throughout the body, making assessment and quantification of spasticity challenging but important. Assessment tools include those quantified by clinicians, instrumentation, and patients. RECENT FINDINGS: Most tools for measuring spasticity are based on clinician scoring, were developed many years ago, and have undergone minimal recent advances. More recent developments are patient-reported outcome measures for spasticity, including the Numeric Rating Scale for Spasticity (NRS-S) and the disease-specific Multiple Sclerosis Spasticity Scale-88 (MSSS), and, most recently, imaging through elastography. MS-related spasticity is common and often disabling. There are various spasticity measurement tools available, each with advantages and limitations. Newer tools are likely to be developed as our understanding of spasticity in MS grows.
Authors: J C Hobart; A Riazi; A J Thompson; I M Styles; W Ingram; P J Vickery; M Warner; P J Fox; J P Zajicek Journal: Brain Date: 2005-11-09 Impact factor: 13.501
Authors: Muhannad M Alsharidah; Mohammad Uzair; Sarah S Alseneidi; Afnan A Alkharan; Reem Fahd Bunyan; Shahid Bashir Journal: Innov Clin Neurosci Date: 2022 Jan-Mar